Form 4: Bio-Rad Laboratories EVP James Barry Reports Stock Transactions
SEC Form 4 Filing
James Barry, EVP and President of Life Science Group at Bio-Rad Laboratories, reports multiple transactions involving Bio-Rad Class A common stock, including acquisitions from restricted stock unit vesting and sales on the open market.
Summary
- James Barry, an executive at Bio-Rad Laboratories, filed a Form 4 detailing changes in his beneficial ownership of Bio-Rad Class A common stock.
- The reported transactions include the acquisition of shares through the vesting of restricted stock units (RSUs) and the disposal of shares through sales.
- On various dates from September 1 to September 4, 2024, Barry acquired shares as RSUs vested, with vesting amounts ranging from 173 to 265 shares per vesting event.
- Simultaneously, Barry disposed of shares to cover tax obligations related to the vesting of RSUs, with prices ranging from $334.31 to $337.32.
- On September 4, 2024, Barry sold 623 shares at a weighted average price of $330.4946, with individual transaction prices ranging from $330.40 to $330.63.
- Following these transactions, Barry directly owns 146.555 shares of Bio-Rad Class A common stock and holds derivative securities in the form of restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Executive stock transactions are common across publicly traded companies, particularly in the life sciences and diagnostics sectors where Bio-Rad operates.
- Similar filings are regularly made by executives at companies like Danaher, Thermo Fisher Scientific, and Agilent Technologies.
- The vesting of RSUs and subsequent sales to cover tax obligations are standard practices.
- The reported transactions are within the normal range for executive compensation and stock management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased transparency of executive stock ownership.
- The transactions are unlikely to significantly affect employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 09/01/2019 | Grant date of 1,083 restricted stock units vesting in five equal annual installments. |
| 09/02/2020 | Grant date of 1,059 restricted stock units vesting in four equal annual installments. |
| 09/01/2021 | Grant date of 709 restricted stock units vesting in four equal annual installments. |
| 09/01/2022 | Grant date of 694 restricted stock units vesting in four equal annual installments. |
| 09/01/2023 | Grant date of 1,002 restricted stock units vesting in four equal annual installments. |
| 06/30/2024 | Date of acquisition of 45.6820 shares under the Bio-Rad Employee Stock Purchase Plan. |
| 09/01/2024 | Multiple transactions involving vesting of RSUs and disposal of shares. |
| 09/02/2024 | Multiple transactions involving vesting of RSUs and disposal of shares. |
| 09/03/2024 | Multiple transactions involving vesting of RSUs and disposal of shares. |
| 09/04/2024 | Sale of 623 shares at a weighted average price of $330.4946. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.